ANDA 205648, held by Qilu Pharm Hainan. Palonosetron Hydrochloride.
As of Nov 16, 2026, ANDA 205648 (Palonosetron Hydrochloride), held by Qilu Pharm Hainan, was first approved by FDA on Sep 19, 2018, with 1 approved supplement and 0 published complete response letters.
Palonosetron Hydrochloride Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2018 | Original application | Approved |
| Palonosetron HydrochlorideEQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Rx |
| Palonosetron HydrochlorideEQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) · injectable;intravenous | Palonosetron Hydrochloride | Discontinued |
| Aug 25, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 19, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters